Plain-English translation of NCT05780905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 2 research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers know that semaglutide, a medication used to treat type 2 diabetes, may help reduce the risk of stroke. This study is testing whether semaglutide improves blood flow inside the brain and strengthens the protective barrier around the brain. You'll receive either the medication or a placebo (inactive pill) for one year while researchers use special brain imaging to see if the treatment makes a difference.
People with type 2 diabetes often have reduced blood flow to their brains, which can increase stroke risk. Early research suggests this medication may protect the brain, but doctors want to understand exactly how it works and confirm it's truly helpful.
You likely qualify if…
You likely don't qualify if…
You'll visit the research center regularly over one year. At each visit, researchers will check your blood sugar, blood pressure, and other health markers. You'll also undergo special brain imaging scans (MRI) to measure blood flow. You'll either take the study medication or a placebo by injection once a week, and a diabetes specialist will work with you to keep your blood sugar well-controlled throughout the study. A care team will monitor you closely to make sure you stay healthy.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States